These changes largely emulated alterations we observed in the human sporadic AD hippocampus: reduced SPHK1, SPHK2, CERK, S1PR1, and BCL2. We observed that the responses to FTY720 treatment were modified by age and notably differed between control (APP−) and AD transgenic (APP+) animals. This evidence concerns the gene S1PR1 and Alzheimer disease.